Blood-based Biomarkers for Early Alzheimer's Disease Screening
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are: * to identify core blood biomarker suitable for early screening of AD. * to establish a comprehensive model for the early identification of AD.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: t
View:
• Age ≥ 50 years;
• AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;
• Signed informed consent form.
Locations
Other Locations
China
Peking University First Hospital
RECRUITING
Beijing
Contact Information
Primary
Chen Zhang
chenzizm@126.com
86+83572462
Time Frame
Start Date: 2024-06-18
Estimated Completion Date: 2026-03-26
Participants
Target number of participants: 180
Treatments
different stages of individuals with Alzheimer's disease
Related Therapeutic Areas
Sponsors
Leads: Peking University First Hospital